Abstract
While gas chromatography-mass spectrometry (GC/MS) continues to be the forensic standard for toxicology, liquid chromatography coupled to tandem MS offers significant operational advantages for targeted confirmatory analysis. LC-high-resolution (HR)-MS has recently been available that offers advantages for untargeted analysis. HR-MS analyzers include the Orbitrap and time-of-flight MS. These instruments are capable of detecting 1 ppm mass resolution. Following soft ionization, this enables the assignment of exact molecular formula, limiting the number of candidate compounds. With this technique, presumptive identification of unknowns can be conducted without the need to match MS library spectra or comparison against known standards. For clinical toxicology, this can greatly expand on the number of drugs and metabolites that can be detected and reported on a presumptive basis. Definitive assignments of the compound’s identity can be retrospectively determined with acquisition of the appropriate reference standard.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Renagarajan A, Mullins ME (2013) How often do false-positive phencyclidine urine screens occur with use of common medications? Clin Toxicol (Phila) 51(6):493–496
Wenk RE (2006) False-negative urine immunoassay after lorazepam overdose. Arch Pathol Lab Med 130:1600–1601
Wu AHB, Gerona R, Armenian P, French D, Petrie M, Lynch KL (2012) Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol 50:733–742
Ojanpera I, Kolmonen M, Pelander A (2012) Current use of high-resolution mass spectrometry in drug screening relevant to clinical and forensic toxicology and doping control. Anal Bioanal Chem 403:1203–1220
Crews BO, Pesce AJ, West R, Nguye H, Fitzgerald RL (2012) Evaluation of high-resolution mass spectrometry for urine toxicology screening in a pain management setting. J Anal Toxicol 36:601–607
Croley TR, White KD, Callahan JH, Musser SM (2012) The chromatographic role in high resolution mass spectrometry for non-targeted analysis. J Am Soc Mass Spectrom 23:1569–1578
Bush DM (2008) The U.S. Mandatory Guidelines for Federal Workplace Drug Testing Programs: current status and future considerations. Forensic Sci Int 174:111–119
Jarvie DR, Simpson D (1986) Drug screening: evaluation of the Toxi-lab TLC system. Ann Clin Biochem 23:76–84
Demedts P, Wauters A, Franck F, Neels H (1994) Evaluation of the Remedi drug profiling system. Eur J Clin Chem Clin Biochem 32:409–417
Gerona RR, Wu AH (2012) Bath salts. Clin Lab Med 32(3):415–427
Fattore L, Fratta W (2011) Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5(60):1–12
Stogner JM (2014) The potential threat of acetyl fentanyl: legal issues, contaminated heroin, and acetyl fentanyl “disguised” as other opioids. Ann Emerg Med 64(6):637–639
Petrie MS, Lynch KL, Wu AHB, Steinhardt AA, Horowitz GL (2012) Prescription compliance or illicit designer drug abuse? Clin Chem 58:1631–1635
Graf J, Lynch K, Yeh CL, Tarter L, Richman N, Nguyen T, Kral A, Dominy S, Imboden J (2011) Purpura, cutaneous necrosis, and antineutrophil cytoplasmic antibodies associated with levamisole-adulterated cocaine. Arthritis Rheum 63:3998–4001
Title 21 US Code (USC) Controlled Substance Act. US Department of Justics, Drug Enforcement Agency. Office of Diversion Control. http://www.deadiversion.ucdoj.gov/21cfr/21usc/812.htm
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Wu, A.H.B., Colby, J. (2016). High-Resolution Mass Spectrometry for Untargeted Drug Screening. In: Garg, U. (eds) Clinical Applications of Mass Spectrometry in Drug Analysis. Methods in Molecular Biology, vol 1383. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3252-8_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3252-8_17
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3251-1
Online ISBN: 978-1-4939-3252-8
eBook Packages: Springer Protocols